BIO says IPR exemption won't increase Medicare costs

The Biotechnology Industry Organization believes that a Congressional Budget Office estimate of the cost of proposed patent reforms is based on faulty assumptions, BIO General Counsel Tom DiLenge told BioCentury.

The CBO has made a preliminary estimate that a

Read the full 391 word article

How to gain access

Continue reading with a
two-week free trial.